Plaque, Amyloid
-
Subject Areas on Research
- APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.
- Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing.
- Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.
- Alzheimer disease: what changes in the brain cause dementia?
- An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction.
- Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
- Cerebrovascular smooth muscle actin is increased in nondemented subjects with frequent senile plaques at autopsy: implications for the pathogenesis of Alzheimer disease.
- Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.
- Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers.
- Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
- Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy.
- Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
- Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.
- Human apolipoprotein E2 promotes parenchymal amyloid deposition and neuronal loss in vasculotropic mutant amyloid-β protein Tg-SwDI mice.
- Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
- Iatrogenic Alzheimer Disease? Amyloid-β Protein Transmission Between Humans.
- Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.
- In vivo amyloid imaging in Alzheimer's disease.
- Increased expression of p130 in Alzheimer disease.
- Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.
- Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.
- Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.
- Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.
- Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
- Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer's disease.
- Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
- Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.
- The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden.
- Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia.
- Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
- Vascular dementia: atherosclerosis, cognition and Alzheimer's disease.
- Willingness to Undergo a Risky Treatment to Improve Cognition Among Persons With Cognitive Impairment Who Received an Amyloid PET Scan.
-
Keywords of People
- Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
- Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology